Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, MD, Jason Gotlib, MD MS, Sanjay Mohan, MD MSCI, Haris Ali, MD, Ekatherine Asatiani, MD, Francis Seguy, Feng Zhou, Srdan Verstovsek, MD PhD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-134574

Published: 2020

Journal Articles

Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias

Karolyn A. Oetjen, MDPhD, Diane E. Bender, PhD, Marianna B. Ruzinova, MDPhD, Daniel A.C. Fisher, PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-142238

Published: 2020

Journal Articles

A Novel Humanized Animal Model Reveals Clonal Architecture and Therapeutic Vulnerabilities in Myelofibrosis

Hamza Celik, PhD, Ethan Krug, Hassan Bjeije, PhD, Nancy Issa, MD, Wentao Han, Won Kyun Koh, Ruochao CZ Zhang, PhD, Maggie J. Allen, Terrence N Wong, MD PhD, Daniel AC Fisher, PhD, Tiandao Li, Stephen T. Oh, MD PhD, Grant A. Challen, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-143034

Published: 2020

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells

Taylor B. Collins, Stephanie A. Luff, PhD, Luis F.Z. Batista, PhD, Christopher M. Sturgeon, PhD, Stephen T. Oh, MD

Blood (2019) 134 (Supplement_1): 2971.

https://doi.org/10.1182/blood-2019-130541

Published: 2019

Journal Articles

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Tianjiao Wang, BA, Hua Sun, PhD, Daniel Cui Zhou, BA, Ruiyang Liu, BS, Lijun Yao, MS, Mark A. Fiala, MSW, Daniel R. Kohnen, MBA, Julie O'Neal, PhD, Michael P. Rettig, PhD, Jared S Fowles, PhD, Stephen T. Oh, MD, Reyka G Jayasinghe, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD, Li Ding, PhD

Blood (2019) 134 (Supplement_1): 364.

https://doi.org/10.1182/blood-2019-131361

Published: 2019

Journal Articles

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Karolyn A. Oetjen, MD, Diane E. Bender, PhD, Marianna B. Ruzinova, MD PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 3728.

https://doi.org/10.1182/blood-2019-127460

Published: 2019

Journal Articles

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Amy Zhou, MD, Stephen T. Oh, MD

Blood (2019) 134 (Supplement_1): 4210.

https://doi.org/10.1182/blood-2019-131128

Published: 2019

Journal Articles

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Jennifer O'Sullivan, MD, Jason A Taylor, MD PhD, Aaron T. Gerds, MD MS, Sarah A Buckley, MD, Claire N Harrison, Professor, Stephen T. Oh, MD, Kieran Howard, Helene Marie-Pierre Dreau, PhD, Angela Hamblin, MD PhD, Adam J. Mead, MD PhD

Blood (2019) 134 (Supplement_1): 4214.

https://doi.org/10.1182/blood-2019-129254

Published: 2019

Journal Articles

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

Amy Zhou, MD, Maggie J. Allen, Mary Fulbright, Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2018-99-113661

Published: 2018

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients with Polycythemia Vera

Jared S Fowles, PhD, Chi-Joan How, MD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2018-99-111573

Published: 2018

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Daniel A.C. Fisher, PhD, Cathrine A. Miner, Elizabeth K. Engle, PhD, Taylor M. Brost, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4277.

https://doi.org/10.1182/blood.V128.22.4277.4277

Published: 2016

Journal Articles

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

Shovik Bandyopadhyay, Liyang Yu, Daniel A.C. Fisher, PhD, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4278.

https://doi.org/10.1182/blood.V128.22.4278.4278

Published: 2016

Journal Articles

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Brady L. Stein, MD, Ahmad Naim, MD, Michael R. Grunwald, MD, Alison R. Moliterno, MD, Stephen T. Oh, MD PhD, Dilan Paranagama, PhD, Joseph A. Cordaro, PharmD, MBA, Hao Sun, MS, Shreekant Parasuraman, BPharm, PhD, Ralph V. Boccia, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 1934.

https://doi.org/10.1182/blood.V128.22.1934.1934

Published: 2016

Journal Articles

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Stephen T. Oh, MD PhD, Christopher A. Miller, PhD, Yevgeniy Gindin, PhD, Taylor M. Brost, Jason Chan, MD PhD, Mary C. Fulbright, Daniel A.C. Fisher, PhD, Eric J. Duncavage, MD, Michelle O'Laughlin, Malachi Griffith, PhD, Obi L. Griffith, PhD, Lukas D. Wartman, MD

Blood (2016) 128 (22): 5496.

https://doi.org/10.1182/blood.V128.22.5496.5496

Published: 2016

Journal Articles

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Seamus B Hughes, David Spiciarich, Richard D. Press, Sarah L Thompson, Jerald P. Radich, Carolyn Bertozzi, Stephen T. Oh, MD PhD, Julia E. Maxson, PhD

Blood (2016) 128 (22): 3141.

https://doi.org/10.1182/blood.V128.22.3141.3141

Published: 2016

NARROW

A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias

A Novel Humanized Animal Model Reveals Clonal Architecture and Therapeutic Vulnerabilities in Myelofibrosis

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells

Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients with Polycythemia Vera

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only